New Biotherapies Push Tecmological Innovation Forward
Pharmaceutical Technology Europe
; 33(6):9-13, 2021.
Artículo
en Inglés
| ProQuest Central | ID: covidwho-20239802
ABSTRACT
[...]on the positive side, innovations in the use of synthetic raw materials and disposable equipment are expected to enhance manufacturing process development, she says. "The AttenuBlock platform incorporates 10 years of research and development at Emory University, where researchers employed rational and precise codon deoptimization and other genetic strategies to produce hundreds of targeted mutations into the RSV genome, providing exquisite control over viral protein expression," Moore explains. [...]the dose of a live attenuated vaccine is typically much lower than all the other non-replicating vaccine types, including genetic (RNA/DNA), viral vectors, protein subunit, inactivated, and virus-like particles (VLPs). [...]to meet global supply and demand, Meissa is implementing straightforward, economical, and scalable vaccine manufacturing technologies, Moore says. [...]licensed VLP vaccines are extremely effective.
Pharmacy And Pharmacology; Innovations; Pathogens; COVID-19 vaccines; Severe acute respiratory syndrome coronavirus 2; Medical research; Manufacturers; Respiratory syncytial virus; Viruses; Antigens; Manufacturing; Poliomyelitis; Research & development--R&D; Technology; Cell culture; Drug dosages; Disease transmission; Proteins; United States--US
Buscar en Google
Colección:
Bases de datos de organismos internacionales
Base de datos:
ProQuest Central
Tópicos:
Vacunas
Idioma:
Inglés
Revista:
Pharmaceutical Technology Europe
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS